THIS PROMOTIONAL SYMPOSIUM HAS BEEN ORGANISED AND FUNDED BY TAKEDA AND IS INTENDED FOR UK HEALTHCARE PROFESSIONALS.

PRESCRIBING AND ADVERSE EVENT REPORTING INFORMATION CAN BE FOUND AT THE BOTTOM OF THE PAGE.

Fruzaqla® (fruquintinib) capsules

Beyond the Trial Data: Real-World Experience with FRUZAQLA▼ (fruquintinib) and Optimising Care in 3L+ mCRC

Thursday 5th November | 17:00–17:45

The Queens Hotel, New Station Street, City Square, Leeds, LS1 1PJ

Two years on from the UK approval of FRUZAQLA[1], **join us to reflect on how use in the 3L+ mCRC setting has evolved in clinical practice.**

Chaired by Dr Sheela Rao, this interactive meeting will bring together real-world experiences of prescribing FRUZAQLA, with practical discussion around patient management and the integration of best supportive care.

We hope you can join us for an engaging exchange of experiences and perspectives.

This session will include valuable insights from our speakers



Dr Sheela Rao
Consultant Medical Oncologist, The Royal Marsden



Charlie Brown
CNS, East Suffolk & North Essex NHS FT



Dr Michael Braun
Consultant in Medical Oncology, The Christie

Agenda

17:00 **Welcome and Introduction**
Dr Sheela Rao

17:05 **FRUZAQLA: From Clinical Trial Evidence to Real-World Practice**
Dr Sheela Rao

17:15 **A Single Centre's Real-World Use of FRUZAQLA: Experience, Outcomes and Lessons Learned**
Dr Michael Braun

17:25 **Integrating Best Supportive Care in the 3L+ mCRC Setting: Practical Considerations and Case Discussion**
Charlie Brown

17:35 **Panel Discussion, Q&A and Close**
All speakers

FRUZAQLA is indicated for the treatment of adult patients with metastatic colorectal cancer (mCRC) who have been previously treated with available therapies, including fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, with or without an anti-VEGF therapy, and, if *RAS* wild-type and medically appropriate, an anti-EGFR therapy.[1]

Click here to access FRUZAQLA prescribing information

3L+ = third-line or later; CNS = clinical nurse specialist; CRC = colorectal cancer; EGFR = epidermal growth factor receptor; mCRC = metastatic colorectal cancer; NHS FT = National Health Service Foundation Trust; Q&A = question and answer; UK = United Kingdom; VEGF = vascular endothelial growth factor.

1. FRUZAQLA Summary of Product Characteristics.

Adverse events should be reported. Reporting forms and information can be found at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store. Adverse events should also be reported to Takeda at: AE.GBR-IRL@takeda.com

C-APROM/GB/FRQ/0035 | September 2026

Colonnections

Takeda